$HBIO· SEC filing ·

HBIO Reports $23.7M Q4 Revenue, 60% Gross Margin, +27% Adjusted EBITDA; Outlines Strategy for Translational Science Growth

Harvard Bioscience Inc · LABORATORY ANALYTICAL INSTRUMENTS · Now $6.40

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS